Quanterix Co. (NASDAQ:QTRX - Get Free Report) Director David R. Walt purchased 36,010 shares of the firm's stock in a transaction dated Thursday, June 12th. The stock was acquired at an average cost of $6.23 per share, for a total transaction of $224,342.30. Following the purchase, the director now owns 1,742,943 shares in the company, valued at approximately $10,858,534.89. The trade was a 2.11% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link.
Quanterix Trading Up 1.8%
QTRX traded up $0.11 during mid-day trading on Monday, hitting $6.17. 662,158 shares of the stock were exchanged, compared to its average volume of 587,393. The firm's fifty day moving average is $5.37 and its two-hundred day moving average is $7.66. Quanterix Co. has a 1-year low of $4.05 and a 1-year high of $16.74. The company has a market cap of $239.57 million, a PE ratio of -5.82 and a beta of 1.05.
Quanterix (NASDAQ:QTRX - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.16. The firm had revenue of $30.33 million for the quarter, compared to analyst estimates of $28.27 million. Quanterix had a negative return on equity of 11.74% and a negative net margin of 30.12%. As a group, research analysts anticipate that Quanterix Co. will post -0.98 earnings per share for the current year.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the business. Jane Street Group LLC increased its holdings in shares of Quanterix by 4.2% in the 1st quarter. Jane Street Group LLC now owns 58,313 shares of the company's stock valued at $380,000 after acquiring an additional 2,366 shares during the last quarter. SCS Capital Management LLC purchased a new position in shares of Quanterix in the 1st quarter valued at about $2,307,000. Goldman Sachs Group Inc. grew its stake in Quanterix by 20.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 349,696 shares of the company's stock worth $2,277,000 after buying an additional 59,655 shares during the last quarter. Invenomic Capital Management LP acquired a new stake in Quanterix during the 1st quarter worth approximately $5,872,000. Finally, AQR Capital Management LLC lifted its position in Quanterix by 204.4% during the 1st quarter. AQR Capital Management LLC now owns 98,990 shares of the company's stock worth $644,000 after acquiring an additional 66,470 shares during the period. Hedge funds and other institutional investors own 86.48% of the company's stock.
Analyst Upgrades and Downgrades
Several equities analysts have recently commented on QTRX shares. Scotiabank reaffirmed an "outperform" rating on shares of Quanterix in a research note on Tuesday, March 25th. Canaccord Genuity Group decreased their price target on Quanterix from $15.00 to $12.00 and set a "buy" rating on the stock in a research note on Tuesday, May 13th. Wall Street Zen lowered Quanterix from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Leerink Partners reaffirmed a "market perform" rating and issued a $8.00 price target (down previously from $12.00) on shares of Quanterix in a research note on Wednesday, April 30th. Finally, Leerink Partnrs lowered Quanterix from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $15.60.
Check Out Our Latest Stock Analysis on Quanterix
Quanterix Company Profile
(
Get Free Report)
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.
Further Reading
Before you consider Quanterix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Quanterix wasn't on the list.
While Quanterix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
